Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ray Lin
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered With PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Effect of Subcutaneous Pressure on Interface Pressure Measurement During Compression Therapy
Veins and Lymphatics
Related publications
Phase Ia Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) in Patients With Recurrent Advanced Solid Tumors
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
Indoleamine 2,3-Dioxygenase 1 (IDO1)
Science-Business eXchange
Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients With Refractory, Locally Advanced or Metastatic Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Mapping the Binding Trajectory of a Suicide Inhibitor in Human Indoleamine 2,3 Dioxygenase 1
Biophysical Journal
Biophysics
O3-2-5a Phase I Trial of BI 754091, a Programmed Death Receptor 1 (PD-1) Inhibitor, in Patients With Advanced Solid Tumors
Annals of Oncology
Medicine
Oncology
Hematology
Phase I Study of the Pan-Pi3k Inhibitor Buparlisib in Adult Chinese Patients With Advanced Solid Tumors
Anticancer Research
Medicine
Cancer Research
Oncology
First-In-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients With Advanced Solid Tumors
Clinical Cancer Research
Cancer Research
Oncology
Phase I Study of the mTOR Inhibitor Ridaforolimus and the HDAC Inhibitor Vorinostat in Advanced Renal Cell Carcinoma and Other Solid Tumors
Investigational New Drugs
Oncology
Pharmacology
A Phase I Study of BI 811283, an Aurora B Kinase Inhibitor, in Patients With Advanced Solid Tumors
Cancer Chemotherapy and Pharmacology
Cancer Research
Toxicology
Oncology
Pharmacology
